1 International Diabetes Federation 20062 The Challenge of obesity in the WHO European Region and the strategies for response. Nov. 2006 ( ADA / EASD-Konsensus Leitlinie 2008: Nathan et al. Management of hyperglycaemia in type 2 diabetes mellitus: a conxensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 2008; 51: 8 – 114 Arzneimittelkompendium der Schweiz5 Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2, Update der Evidenzbasierten Leitlinien der Deutschen Diabetes Gesellschaft, Oktober 20086 Kappeler T. Glimepirid, pharma-kritik, Jahrgang 17, Nr. 20, 19967 diabetesmanager: Oral Pharmacological Agents for Type 2 Diabetes, November 20088 BAG, SL, 01.11.20099 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group; Lancet 1998, Sept 12, 352 (9131): 854-865.
10 Neal B et al. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure- lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000;356:1955-1964.
11 Fliser D et al. EUTOPIA - European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis. Circulation 2004; 110: 110312 Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr Med Res Opin 2001; 17(1): 8 – 17 13 Dahlöf B et al. Cardiovascular morbidity and mortality in the losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995–100314 Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20; 345(12): 861–9.
15 Hedner T et al. The clinical profile of the angiotensin II receptor blocker eprosartan. J. Hypertens. Suppl. 2002; 20(5): 533 – 53816 Kobstam MA. et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Am Herat J. 2005, 150(1), 123 –131.
17 Dickstein K. et al. Effects of losartan and captopril on mortality and morbidity in high- risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002, 360. 752 – 760.
18 Prospective Study of the Elderly at Risk (Doppelblinde, randomisierte, plazebo- kontrollierte Studie) Circulation 103, 357, 200119 Hunninghake D.B. et al. Comparative effects of simvastatin ans atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 25, 1670–1686, 2003 * Valables uniquement pour la monosubstance losartan


Ministero dell’università e della ricerca

Rivista Scientifica fondata nel 1945 da Gaetano Del Vecchio già diretta da Gaetano e Vittorio Del Vecchio Sed prior est sanitas quam sit curatio morbi APPENDICE Versione semplificata della cartella clinica utilizzata nel progetto di ricerca Intervento integrato di accoglienza, trattamento, orientamento ed indirizzo per tossicodipendenti e soggetti a rischio Periodico bimestr

Microsoft word - mast cell tumors in dogs

Mast cells are normal cells of the immune system, which start in the bone marrow and then mature in the skin, the digestive tract, and other tissues. Mast cell tumors occur when one of these cells begins dividing uncontrollably and form a lump. Mast cell tumors are the most common malignant skin cancer in dogs. They can also form in the internal organs. A genetic predisposition is suspected, bu

Copyright © 2010-2014 Drug Shortages pdf